Predict your next investment

Caris Life Sciences company logo
Corporation
HEALTHCARE | Biotechnology
carislifesciences.com

See what CB Insights has to offer

Competitors

2

Business Relationships

10

Caris Life Sciences Competitors & Alternatives

2 Competitors

Caris Life Sciences has 2 competitors. Caris Life Sciences's competitors are Strata Oncology and more.

Latest Funding

Companies

Investment Stage

Total Funding

Mosaic
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

Location

7/28/2021

Series C

$133M

Michigan

00/00/0000

Subscribe to see more

Subscribe to see more

$99M

Subscribe to see more

Latest Funding

7/28/2021

00/00/0000

Companies

Subscribe to see more

Investment Stage

Series C

Subscribe to see more

Total Funding

$133M

$99M

Mosaic

Location

Michigan

Subscribe to see more

Caris Life Sciences Partners & Customers

10 Partners and customers

Caris Life Sciences has 10 strategic partners and customers. Caris Life Sciences recently partnered with ESSA Pharma on October 10, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

10/7/2021

Partner

ESSA Pharma

Canada

06:30 ET Caris Life Sciences and ESSA Pharma Announce Liquid Biopsy Profiling Collaboration

Forward-looking information involves statements that relate to future events and often addresses expected future business and financial performance , containing words such as `` anticipate '' , `` believe '' , `` plan '' , `` estimate '' , `` expect '' , and `` intend '' , statements that an action or event `` may '' , `` might '' , `` could '' , `` should '' , or `` will '' be taken or occur , or other similar expressions and includes , but is not limited to , statements regarding ESSA Pharma Inc. 's utilization of the data from the collaboration with Caris Life Sciences to better characterize the tumor biological profiles of patients in the ongoing monotherapy clinical trial of EPI-7386 in mCRPC patients and ESSA Pharma Inc. 's belief that the platform provided by Caris Life Sciences ' WTS and WES will provide important biological information at the individual patient level and may facilitate a more efficient development of EPI-7386 in patients with prostate cancer through the identification of relevant patient tumor biological subpopulations .

2

5/20/2021

Partner

National Cancer Center Japan

Japan

06:30 ET Caris Life Sciences and National Cancer Center Japan Announce Exclusive Collaboration to Launch The SCRUM-Japan MONSTAR...

IRVING , Texas , May 20 , 2021 / PRNewswire / -- Caris Life Sciences , a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine , announced today they have entered into an exclusive collaboration agreement with the National Cancer Center Japan to provide Caris Life Sciences ' comprehensive molecular profiling in MONSTAR-SCREEN-2 of SCRUM-Japan , the largest cancer genomic screening consortium in Japan .

3

9/22/2020

Partner

UT Southwestern Medical Center

United States

Caris Precision Oncology Alliance Welcomes UT Southwestern Medical Center

Through the Caris , UT Southwestern Medical Center will partner with other prominent cancer centers and academic institutions to broaden patient access to precision cancer care , have early access to Caris ™ offerings , and establish evidence-based standards for cancer profiling and molecular testing in oncology .

1

8/25/2020

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

8/13/2020

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

10/7/2021

5/20/2021

9/22/2020

8/25/2020

8/13/2020

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

ESSA Pharma

National Cancer Center Japan

UT Southwestern Medical Center

Country

Canada

Japan

United States

Subscribe to see more

Subscribe to see more

News Snippet

06:30 ET Caris Life Sciences and ESSA Pharma Announce Liquid Biopsy Profiling Collaboration

Forward-looking information involves statements that relate to future events and often addresses expected future business and financial performance , containing words such as `` anticipate '' , `` believe '' , `` plan '' , `` estimate '' , `` expect '' , and `` intend '' , statements that an action or event `` may '' , `` might '' , `` could '' , `` should '' , or `` will '' be taken or occur , or other similar expressions and includes , but is not limited to , statements regarding ESSA Pharma Inc. 's utilization of the data from the collaboration with Caris Life Sciences to better characterize the tumor biological profiles of patients in the ongoing monotherapy clinical trial of EPI-7386 in mCRPC patients and ESSA Pharma Inc. 's belief that the platform provided by Caris Life Sciences ' WTS and WES will provide important biological information at the individual patient level and may facilitate a more efficient development of EPI-7386 in patients with prostate cancer through the identification of relevant patient tumor biological subpopulations .

06:30 ET Caris Life Sciences and National Cancer Center Japan Announce Exclusive Collaboration to Launch The SCRUM-Japan MONSTAR...

IRVING , Texas , May 20 , 2021 / PRNewswire / -- Caris Life Sciences , a leading innovator in molecular science and artificial intelligence focused on fulfilling the promise of precision medicine , announced today they have entered into an exclusive collaboration agreement with the National Cancer Center Japan to provide Caris Life Sciences ' comprehensive molecular profiling in MONSTAR-SCREEN-2 of SCRUM-Japan , the largest cancer genomic screening consortium in Japan .

Caris Precision Oncology Alliance Welcomes UT Southwestern Medical Center

Through the Caris , UT Southwestern Medical Center will partner with other prominent cancer centers and academic institutions to broaden patient access to precision cancer care , have early access to Caris ™ offerings , and establish evidence-based standards for cancer profiling and molecular testing in oncology .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

3

1

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.